Responsiveness to curcumin intervention is associated with reduced aortic stiffness in young, obese men with higher initial stiffness. (February 2017)

• Record Type: Journal Article
• Authors: Campbell, Marilyn S.; Berrones, Adam J.; Krishnakumar, I.M.; Charnigo, Richard J.; Westgate, Philip M.; Fleenor, Bradley S.
• Is Part Of: Journal of functional foods. Volume 29(2017)
• Page Start: 154
• Page End: 160
• Publication Date: 2017-02
• Subjects: BMI body mass index -- BP blood pressure -- CCTS Center for Clinical and Translational Science -- cfPWV carotid-femoral Pulse Wave Velocity -- CGM CurQfen -- CV events cardiovascular events -- CVD cardiovascular disease -- DBP diastolic blood pressure -- EKG electrocardiogram -- IFN Interferon -- IL Interleukin -- NFκB Nuclear Factor Kappa Beta -- PP pulse pressure -- SBP systolic blood pressure -- SD standard deviation -- TNF-α Tumor Necrosis Factor Alpha; Turmeric -- Vascular function -- Body composition -- Obesity -- Inflammation -- Bioavailability; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2016.12.013
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: CurQfen®, a novel curcumin compound, reduces brachial pulse pressure in obese men. Aortic stiffness was reduced by CurQfen® in subjects with increased baseline values. Interleukin-13 is inversely related to aortic stiffness in CurQfen® responders. Abstract: Obesity results in greater aortic stiffness assessed by carotid-femoral Pulse Wave Velocity (cfPWV), which is an independent predictor of cardiovascular (CV) events. We hypothesized that a novel curcumin formulation with enhanced bioavailability, CurQfen®, would reduce cfPWV and inflammation in young, obese men. In the present placebo-controlled pilot study, 22 obese subjects (BMI ⩾ 30.0 kg/m 2 ) were randomized into placebo (n = 11, BMI = 33.18 ± 3.38 kg/m 2 ) and curcumin (n = 11, BMI = 33.29 ± 3.69 kg/m 2 ) supplemented groups. When CurQfen® was supplemented at 500 mg/day for 12 weeks, it was found that individuals who did respond to the treatment (n = 6) entered the study with higher baseline cfPWV versus those who did not respond (n = 5) (6.81 ± 0.83 m/s v. 5.84 ± 0.41 m/s, p = 0.045, group by time interaction). The curcumin responders also had increased plasma IL-13 concentrations (p = 0.018, 12 weeks v. baseline). These findings suggest CurQfen curcumin has potential to de-stiffen arteries in young, obese men with greater aortic stiffness.